Monthly Archives: February 2017
Fee-for-service: an ethical conflict
Andrew Mitchell suggests that innovative institutional changes are needed to sustain universal healthcare in Canada.
Human germline genome editing: An ‘impressive’ sleight of hand?
Françoise Baylis wonders how it is that in 14 months (from December 2015 to February 2017), the U.S. National Academy of Sciences and the U.S. National Academy of Medicine have moved human germline genome editing out of the category ‘irresponsible’ and into the category ‘permissible.’
Using Social Media to Sell Prescription Drugs
Jean-Christophe Bélisle-Pipon and Stanislav Birko consider how direct-to-consumer marketing of prescription drugs using social media might be prevented by amending Canada’s Food and Drug Regulations.
Lupron: Déjà Vu All Over Again
Alice Dreger raises concerns about a pervasive pattern of non-evidence based assumptions driving practices in pediatric endocrinology.
Impact Ethics 